{"title": "Researchers strengthen the link between Epstein-Barr Virus (EBV) and the risk of developing MS - MS International Federation", "author": "Lili White", "url": "https://www.msif.org/news/2022/01/21/researchers-strengthen-the-link-between-epstein-barr-virus-ebv-and-the-risk-of-developing-ms/", "hostname": "msif.org", "description": null, "sitename": "Multiple Sclerosis International Federation", "date": "2022-01-21", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Investigadores consolidan el v\u00ednculo entre el virus de Epstein-Barr (VEB) y el riesgo de desarrollar EM\n\u00bfCausa EM el VEB?\nLast updated: 29th March 2022\n\u00bfQu\u00e9 hay en esta p\u00e1gina?\n\u00bfCausa EM el VEB?\nNo se sabe con certeza qu\u00e9 causa EM, pero probablemente se origine debido a una combinaci\u00f3n de factores gen\u00e9ticos, del entorno y del estilo de vida. Es dif\u00edcil afirmar que un factor por s\u00ed solo definitivamente causa EM o que una combinaci\u00f3n de factores distintos aumenta el riesgo de desarrollar EM. No obstante, un nuevo estudio importante respalda la evidencia que indica que el virus de Epstein-Barr (VEB) podr\u00eda ser uno de esos factores de riesgo.\n\u00bfQu\u00e9 es el VEB?\nEl VEB es un tipo de virus del herpes. Es uno de los virus m\u00e1s comunes, que se encuentra en nueve de cada diez personas en todo el mundo. Se transmite a trav\u00e9s de fluidos corporales, como la saliva. Puede causar mononucleosis infecciosa, tambi\u00e9n conocida como fiebre glandular. Despu\u00e9s de que el cuerpo se recupera de la enfermedad, el VEB permanece \u201clatente\u201d en \u00e9l y crea una infecci\u00f3n oculta de por vida.\n\u00bfC\u00f3mo est\u00e1 relacionado el VEB con EM?\nDespu\u00e9s de que el cuerpo humano combate a un virus, el sistema inmunol\u00f3gico deja partes del invasor detr\u00e1s, que se conocen como ant\u00edgenos. El cuerpo reconoce a los ant\u00edgenos y estimula la producci\u00f3n de anticuerpos para ayudar al sistema inmunol\u00f3gico a reconocer al virus en el caso de una invasi\u00f3n nueva. Los anticuerpos contra el VEB se han vinculado con varios tipos de c\u00e1ncer y enfermedades autoinmunes, entre las que se incluye EM. Los estudios indican que los anticuerpos contra el VEB ocultos pueden interactuar con el sistema inmunol\u00f3gico y el sistema nervioso, y originar la enfermedad.\nDiversos estudios han detectado un v\u00ednculo entre el VEB y EM, y se ha descubierto que el 99 % de las personas con EM ten\u00eda anticuerpos contra el VEB. De manera an\u00e1loga, la mayor\u00eda de las personas sin anticuerpos contra el VEB mostr\u00f3 una tendencia a no desarrollar EM.\n\u00bfQu\u00e9 demuestra la investigaci\u00f3n nueva?\nEl profesor Alberto Ascherio y sus colegas de Harvard T.H. Chan School of Public Health en Cambridge, EUA, realizaron un seguimiento de diez millones de efectivos militares de los EE. UU. a lo largo de veinte a\u00f1os. Quer\u00edan descubrir si la infecci\u00f3n por VEB aumentaba el riesgo de desarrollar EM.\nAl inicio del estudio, tomaron muestras de sangre de todos y registraron el nivel de anticuerpos contra el VEB para determinar si las personas hab\u00edan tenido una infecci\u00f3n por VEB en el pasado. A continuaci\u00f3n, tomaron muestras de sangre cada dos a\u00f1os para evaluar si las personas que no hab\u00edan tenido la infecci\u00f3n anteriormente ahora s\u00ed mostraban indicios de haberla tenido. El grupo tambi\u00e9n registr\u00f3 el nivel de luz del\n[neurofilamento](https://www.msif.org/news/2020/10/15/a-potential-biomarker-for-progressive-ms/) (NfL, por sus siglas en ingl\u00e9s). La NfL consiste en [un biomarcador](https://www.msif.org/news/2021/04/16/what-is-a-biomarker/), es decir, un elemento que nos puede indicar el estado de una enfermedad. A menudo, la NfL se detecta en la sangre de personas que tuvieron alg\u00fan tipo de da\u00f1o cerebral o en el sistema nervioso, como el que sucede cuando la mielina se descompone debido a EM. En las personas que luego desarrollan EM, el nivel de NfL en la sangre es alto hasta seis a\u00f1os de la aparici\u00f3n de s\u00edntomas de EM. Ascherio y sus colegas descubrieron que, en personas con EM, la NfL solo se incrementaba despu\u00e9s de una infecci\u00f3n por VEB. Este descubrimiento llev\u00f3 a que los investigadores consideren que la infecci\u00f3n por VEB se produjo antes del inicio de EM.\nDe los diez millones de personas que participaron en el estudio, 801 recibieron un diagn\u00f3stico de EM, de las cuales 800 ten\u00edan anticuerpos contra el VEB. Se descubri\u00f3 que ten\u00edan 32 veces m\u00e1s riesgo en general de desarrollar EM despu\u00e9s de la infecci\u00f3n por VEB. El grupo tambi\u00e9n analiz\u00f3 otros virus, como el citomegalovirus (CMV), otro virus com\u00fan en los seres humanos. No detectaron ning\u00fan cambio en el riesgo de desarrollar EM despu\u00e9s de la infecci\u00f3n por CMV.\nEl alto incremento en el riesgo en personas infectadas con VEB, junto con la gran cantidad de personas que participaron en el estudio, muestran indicios s\u00f3lidos de que el VEB podr\u00eda ser un factor de riesgo importante para desarrollar EM.\n\u00bfQu\u00e9 significan estos resultados para las personas afectadas por EM?\nEstos resultados indican que los anticuerpos contra el VEB est\u00e1n vinculados con un incremento en el riesgo de desarrollar EM. No obstante, dado que la mayor\u00eda de las personas con una infecci\u00f3n por VEB no desarrollan EM, el VEB por s\u00ed solo no es suficiente para causar EM. Ahora necesitamos comprender por qu\u00e9 algunas personas que se han infectado con VEB desarrollan EM, mientras que otras no.\nExiste un retraso de alrededor de diez a\u00f1os entre la detecci\u00f3n de los anticuerpos contra el VEB y la aparici\u00f3n de los s\u00edntomas de EM. No est\u00e1 claro el motivo, pero cada vez m\u00e1s evidencia indica que existe una fase temprana de EM, denominada fase prodr\u00f3mica. En esta fase, se considera que se est\u00e1 desarrollando EM en el cuerpo, aunque la persona no sufra los s\u00edntomas t\u00edpicos de EM. Durante esta etapa, es posible que los anticuerpos contra el VEB ya est\u00e9n empezando a combatir las defensas de los sistemas inmunol\u00f3gico y nervioso.\nDebido a que no hay una manera de evitar la infecci\u00f3n por VEB, es posible que la vacuna contra el VEB sea la respuesta. Adem\u00e1s, si el VEB constituye un factor de riesgo de EM, ser\u00eda posible desarrollar una vacuna contra el VEB para prevenir EM. Hay muchos investigadores que realizan investigaciones acerca de vacunas contra el VEB, as\u00ed como\n[tratamientos dirigidos contra el VEB en personas que ya tienen EM](https://www.msaustralia.org.au/news/ebv-progressive-ms-trial-three-years-on/). La empresa farmac\u00e9utica Moderna comenz\u00f3 un [ensayo de fase I de una posible vacuna contra el VEB en enero de 2022](https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-First-Participant-Dosed-in-Phase-1-Study-of-its-mRNA-Epstein-Barr-Virus-EBV-Vaccine/default.aspx), para evaluar su seguridad en voluntarios sanos. No sabremos los resultados de estos estudios por un tiempo, pero tendr\u00e1n implicaciones importantes para la prevenci\u00f3n y el tratamiento de EM en el futuro.", "language": null, "image": "http://www.msif.org/wp-content/uploads/2022/01/shutterstock_556379404-scaled.jpg", "pagetype": "article", "links": ["#main-content", "?lang=en", "?lang=ar", "https://donate.msif.org/donate", "https://www.justgiving.com/msif/", "/", "/about-ms/?lang=es", "https://www.msif.org/about-ms/?lang=es", "https://www.msif.org/about-ms/what-is-ms/?lang=es", "https://www.msif.org/about-ms/epidemiology-of-ms/?lang=es", "https://www.msif.org/about-ms/types-of-ms/?lang=es", "https://www.msif.org/about-ms/childhood-ms/?lang=es", "https://www.msif.org/about-ms/causes/?lang=es", "https://www.msif.org/about-ms/diagnosing-ms/?lang=es", "https://www.msif.org/about-ms/symptoms-of-ms/?lang=es", "https://www.msif.org/about-ms/symptoms-of-ms/?lang=es", "https://www.msif.org/about-ms/symptoms-of-ms/bladder-and-bowel-issues/?lang=es", "https://www.msif.org/about-ms/symptoms-of-ms/cognition-and-emotional-changes/?lang=es", "https://www.msif.org/about-ms/symptoms-of-ms/fatigue/?lang=es", "https://www.msif.org/about-ms/symptoms-of-ms/movement-and-coordination-problems/?lang=es", "https://www.msif.org/about-ms/symptoms-of-ms/pain/?lang=es", "https://www.msif.org/about-ms/symptoms-of-ms/sexual-problems/?lang=es", "https://www.msif.org/about-ms/symptoms-of-ms/vision-issues/?lang=es", "/living-with-ms/?lang=es", "https://www.msif.org/living-with-ms/?lang=es", "https://www.msif.org/living-with-ms/find-ms-support-near-you/?lang=es", "https://www.msif.org/news/2020/02/10/the-coronavirus-and-ms-what-you-need-to-know/?lang=es", "https://www.msif.org/living-with-ms/what-influences-quality-of-life/?lang=es", "https://www.msif.org/living-with-ms/what-influences-quality-of-life/?lang=es", "https://www.msif.org/living-with-ms/what-influences-quality-of-life/seven-principles-to-improve-quality-of-life/?lang=es", "https://www.msif.org/living-with-ms/treatments/?lang=es", "https://www.msif.org/living-with-ms/complementary-and-alternative-therapies/?lang=es", "https://www.msif.org/living-with-ms/caregivers/?lang=es", "https://www.msif.org/living-with-ms/rehabilitation/?lang=es", "https://www.msif.org/living-with-ms/family-life/?lang=es", "https://www.msif.org/living-with-ms/relationships-and-intimacy/?lang=es", "https://www.msif.org/living-with-ms/telling-people-you-have-ms-2/?lang=es", "https://www.msif.org/living-with-ms/ageing-and-ms/?lang=es", "https://www.msif.org/living-with-ms/ms-and-menopause/?lang=es", "https://www.msif.org/living-with-ms/keeping-healthy/?lang=es", "https://www.msif.org/living-with-ms/smoking-and-ms/?lang=es", "https://www.msif.org/living-with-ms/education-and-employment/?lang=es", "https://www.msif.org/living-with-ms/international-ms-awards/?lang=es", "https://www.msif.org/living-with-ms/international-ms-awards/?lang=es", "https://www.msif.org/living-with-ms/international-ms-awards/james-d-wolfensohn-award/?lang=es", "https://www.msif.org/living-with-ms/international-ms-awards/evelyn-nicholson-award/?lang=es", "https://www.msif.org/?page_id=432&lang=es", "https://www.msif.org/?page_id=432&lang=es", "https://www.msif.org/access-to-ms-healthcare/?lang=es", "https://www.msif.org/abdelhakim-janati/?lang=es", "https://www.msif.org/living-with-ms/my-story-of-ms/ling-pi/?lang=es", "https://www.msif.org/oumaima-benyaich/?lang=es", "https://www.msif.org/christelle-taute/?lang=es", "https://www.msif.org/sanae-hazim/?lang=es", "https://www.msif.org/living-with-ms/my-story-of-ms/sean-hegarty/?lang=es", "/research/?lang=es", "https://www.msif.org/research/?lang=es", "https://www.msif.org/about-us/who-we-are-and-what-we-do/advocacy/atlas/?lang=es", "https://www.msif.org/research/challenges-of-ms-research/?lang=es", "https://www.msif.org/research/challenges-of-ms-research/?lang=es", "https://www.msif.org/research/challenges-of-ms-research/clinical-trials-and-clinical-developments/?lang=es", "https://www.msif.org/research/challenges-of-ms-research/ms-registries-putting-people-with-ms-at-the-heart-of-research/?lang=es", "https://www.msif.org/proms/?lang=es", "https://www.msif.org/research/challenges-of-ms-research/progressive-ms/?lang=es", "https://www.msif.org/research/challenges-of-ms-research/stem-cell-therapy-for-ms/?lang=es", "https://www.msif.org/research/challenges-of-ms-research/research-into-ms-and-quality-of-life/?lang=es", "https://www.msif.org/research/awards-grants-and-fellowships/?lang=es", "https://www.msif.org/research/awards-grants-and-fellowships/?lang=es", "https://www.msif.org/research/awards-grants-and-fellowships/du-pre-grants/?lang=es", "https://www.msif.org/research/awards-grants-and-fellowships/mcdonald-fellowships/?lang=es", "https://www.msif.org/research/awards-grants-and-fellowships/charcot-award/?lang=es", "https://www.msif.org/research/awards-grants-and-fellowships/young-investigator-award/?lang=es", "https://www.msif.org/research/awards-grants-and-fellowships/global-ms-research-fellowships/?lang=es", "https://www.msif.org/join-us-for-the-june-2023-webcast-on-ending-ms-progression/?lang=es", "/access-to-ms-healthcare/?lang=es", "https://www.msif.org/access-to-ms-healthcare/?lang=es", "https://www.msif.org/access-to-ms-healthcare/improve-access-to-ms-treatment/?lang=es", "https://www.msif.org/access-to-ms-healthcare/improve-ms-diagnosis/?lang=es", "https://www.msif.org/access-to-ms-healthcare/getting-the-healthcare-i-need/?lang=es", "https://www.msif.org/access-to-ms-healthcare/get-the-evidence/?lang=es", "https://www.msif.org/access-to-ms-healthcare/how-to-get-started-in-advocacy/?lang=es", "https://www.msif.org/access-to-ms-healthcare/learn-from-others/?lang=es", "https://www.msif.org/access-to-ms-healthcare/msifs-work-on-access-to-ms-healthcare/?lang=es", "/resources/?lang=es", "/news-and-events/?lang=es", "/about-us/?lang=es", "https://www.msif.org/about-us/?lang=es", "https://www.msif.org/about-us/who-we-are-and-what-we-do/?lang=es", "https://www.msif.org/about-us/our-strategy/?lang=es", "https://www.msif.org/about-us/our-members/?lang=es", "https://www.msif.org/about-us/our-progress-together-were-stronger-than-ms/?lang=es", "https://www.msif.org/about-us/staff/?lang=es", "https://www.msif.org/about-us/governance/?lang=es", "https://www.msif.org/about-us/governance/?lang=es", "https://www.msif.org/about-us/governance/our-committees/board-of-trustees/?lang=es", "https://www.msif.org/about-us/governance/our-committees/?lang=es", "https://www.msif.org/about-us/governance/international-medical-and-scientific-board/?lang=es", "https://www.msif.org/about-us/how-we-are-funded/?lang=es", "https://www.msif.org/about-us/how-we-are-funded/?lang=es", "https://www.msif.org/about-us/how-we-are-funded/our-income-in-2023/?lang=es", "https://www.msif.org/about-us/how-we-are-funded/work-healthcare-industry/?lang=es", "https://www.msif.org/about-us/how-we-are-funded/msif-covid-19-response-initiative/?lang=es", "https://www.msif.org/get-involved/our-supporter-promise/?lang=es", "https://www.msif.org/about-us/reports-and-resources/?lang=es", "https://www.msif.org/about-us/msif-statement-war-and-conflicts-impact-on-people-affected-by-ms/?lang=es", "https://www.msif.org/about-us/msif-statement-war-and-conflicts-impact-on-people-affected-by-ms/?lang=es", "https://www.msif.org/about-us/msif-statement-war-and-conflicts-impact-on-people-affected-by-ms/ukraine/?lang=es", "https://www.msif.org/about-us/contact-us/?lang=es", "/get-involved/?lang=es", "https://www.msif.org/get-involved/?lang=es", "https://www.msif.org/fundraise-for-a-world-without-ms/?lang=es", "https://www.msif.org/get-involved/join-msif/?lang=es", "https://www.msif.org/get-involved/newsletters/?lang=es", "https://www.msif.org/about-us/who-we-are-and-what-we-do/advocacy/world-ms-day/?lang=es", "https://www.msif.org/cykelnerven/?lang=es", "https://www.msif.org/get-involved/our-fundraisers/?lang=es", "https://www.msif.org/get-involved/?lang=es", "https://www.msif.org/fundraise-for-a-world-without-ms/?lang=es", "https://www.msif.org/get-involved/join-msif/?lang=es", "https://www.msif.org/get-involved/newsletters/?lang=es", "https://www.msif.org/about-us/who-we-are-and-what-we-do/advocacy/world-ms-day/?lang=es", "https://www.msif.org/cykelnerven/?lang=es", "https://www.msif.org/get-involved/our-fundraisers/?lang=es", "https://www.msif.org/about-us/msif-statement-war-and-conflicts-impact-on-people-affected-by-ms/?lang=es", "https://www.msif.org/about-us/msif-statement-war-and-conflicts-impact-on-people-affected-by-ms/ukraine/?lang=es", "https://www.msif.org/about-us/how-we-are-funded/?lang=es", "https://www.msif.org/about-us/how-we-are-funded/our-income-in-2023/?lang=es", "https://www.msif.org/about-us/how-we-are-funded/work-healthcare-industry/?lang=es", "https://www.msif.org/about-us/how-we-are-funded/msif-covid-19-response-initiative/?lang=es", "https://www.msif.org/get-involved/our-supporter-promise/?lang=es", "https://www.msif.org/about-us/governance/?lang=es", "https://www.msif.org/about-us/governance/our-committees/board-of-trustees/?lang=es", "https://www.msif.org/about-us/governance/our-committees/?lang=es", "https://www.msif.org/about-us/governance/international-medical-and-scientific-board/?lang=es", "https://www.msif.org/about-us/?lang=es", "https://www.msif.org/about-us/who-we-are-and-what-we-do/?lang=es", "https://www.msif.org/about-us/our-strategy/?lang=es", "https://www.msif.org/about-us/our-members/?lang=es", "https://www.msif.org/about-us/our-progress-together-were-stronger-than-ms/?lang=es", "https://www.msif.org/about-us/staff/?lang=es", "https://www.msif.org/about-us/governance/?lang=es", "https://www.msif.org/about-us/how-we-are-funded/?lang=es", "https://www.msif.org/about-us/reports-and-resources/?lang=es", "https://www.msif.org/about-us/msif-statement-war-and-conflicts-impact-on-people-affected-by-ms/?lang=es", "https://www.msif.org/about-us/contact-us/?lang=es", "https://www.msif.org/access-to-ms-healthcare/?lang=es", "https://www.msif.org/access-to-ms-healthcare/improve-access-to-ms-treatment/?lang=es", "https://www.msif.org/access-to-ms-healthcare/improve-ms-diagnosis/?lang=es", "https://www.msif.org/access-to-ms-healthcare/getting-the-healthcare-i-need/?lang=es", "https://www.msif.org/access-to-ms-healthcare/get-the-evidence/?lang=es", "https://www.msif.org/access-to-ms-healthcare/how-to-get-started-in-advocacy/?lang=es", "https://www.msif.org/access-to-ms-healthcare/learn-from-others/?lang=es", "https://www.msif.org/access-to-ms-healthcare/msifs-work-on-access-to-ms-healthcare/?lang=es", "https://www.msif.org/research/awards-grants-and-fellowships/charcot-award/?lang=es", "https://www.msif.org/research/awards-grants-and-fellowships/charcot-award/charcot-award-winners/?lang=es", "https://www.msif.org/research/awards-grants-and-fellowships/mcdonald-fellowships/?lang=es", "https://www.msif.org/research/awards-grants-and-fellowships/mcdonald-fellowships/mcdonald-fellowship-recipients/?lang=es", "https://www.msif.org/research/awards-grants-and-fellowships/du-pre-grants/?lang=es", "https://www.msif.org/research/awards-grants-and-fellowships/du-pre-grants/du-pre-grant-recipients/?lang=es", "https://www.msif.org/research/awards-grants-and-fellowships/?lang=es", "https://www.msif.org/research/awards-grants-and-fellowships/du-pre-grants/?lang=es", "https://www.msif.org/research/awards-grants-and-fellowships/mcdonald-fellowships/?lang=es", "https://www.msif.org/research/awards-grants-and-fellowships/charcot-award/?lang=es", "https://www.msif.org/research/awards-grants-and-fellowships/young-investigator-award/?lang=es", "https://www.msif.org/research/awards-grants-and-fellowships/global-ms-research-fellowships/?lang=es", "https://www.msif.org/research/challenges-of-ms-research/?lang=es", "https://www.msif.org/research/challenges-of-ms-research/clinical-trials-and-clinical-developments/?lang=es", "https://www.msif.org/research/challenges-of-ms-research/ms-registries-putting-people-with-ms-at-the-heart-of-research/?lang=es", "https://www.msif.org/proms/?lang=es", "https://www.msif.org/research/challenges-of-ms-research/progressive-ms/?lang=es", "https://www.msif.org/research/challenges-of-ms-research/stem-cell-therapy-for-ms/?lang=es", "https://www.msif.org/research/challenges-of-ms-research/research-into-ms-and-quality-of-life/?lang=es", "https://www.msif.org/research/?lang=es", "https://www.msif.org/about-us/who-we-are-and-what-we-do/advocacy/atlas/?lang=es", "https://www.msif.org/research/challenges-of-ms-research/?lang=es", "https://www.msif.org/research/awards-grants-and-fellowships/?lang=es", "https://www.msif.org/join-us-for-the-june-2023-webcast-on-ending-ms-progression/?lang=es", "https://www.msif.org/?page_id=432&lang=es", "https://www.msif.org/access-to-ms-healthcare/?lang=es", "https://www.msif.org/abdelhakim-janati/?lang=es", "https://www.msif.org/living-with-ms/my-story-of-ms/ling-pi/?lang=es", "https://www.msif.org/oumaima-benyaich/?lang=es", "https://www.msif.org/christelle-taute/?lang=es", "https://www.msif.org/sanae-hazim/?lang=es", "https://www.msif.org/living-with-ms/my-story-of-ms/sean-hegarty/?lang=es", "https://www.msif.org/living-with-ms/international-ms-awards/james-d-wolfensohn-award/?lang=es", "https://www.msif.org/living-with-ms/international-ms-awards/james-d-wolfensohn-award/james-d-wolfensohn-award-winners/?lang=es", "https://www.msif.org/living-with-ms/international-ms-awards/?lang=es", "https://www.msif.org/living-with-ms/international-ms-awards/james-d-wolfensohn-award/?lang=es", "https://www.msif.org/living-with-ms/international-ms-awards/evelyn-nicholson-award/?lang=es", "https://www.msif.org/living-with-ms/what-influences-quality-of-life/?lang=es", "https://www.msif.org/living-with-ms/what-influences-quality-of-life/seven-principles-to-improve-quality-of-life/?lang=es", "https://www.msif.org/living-with-ms/?lang=es", "https://www.msif.org/living-with-ms/find-ms-support-near-you/?lang=es", "https://www.msif.org/news/2020/02/10/the-coronavirus-and-ms-what-you-need-to-know/?lang=es", "https://www.msif.org/living-with-ms/what-influences-quality-of-life/?lang=es", "https://www.msif.org/living-with-ms/treatments/?lang=es", "https://www.msif.org/living-with-ms/complementary-and-alternative-therapies/?lang=es", "https://www.msif.org/living-with-ms/caregivers/?lang=es", "https://www.msif.org/living-with-ms/rehabilitation/?lang=es", "https://www.msif.org/living-with-ms/family-life/?lang=es", "https://www.msif.org/living-with-ms/relationships-and-intimacy/?lang=es", "https://www.msif.org/living-with-ms/telling-people-you-have-ms-2/?lang=es", "https://www.msif.org/living-with-ms/ageing-and-ms/?lang=es", "https://www.msif.org/living-with-ms/ms-and-menopause/?lang=es", "https://www.msif.org/living-with-ms/keeping-healthy/?lang=es", "https://www.msif.org/living-with-ms/smoking-and-ms/?lang=es", "https://www.msif.org/living-with-ms/education-and-employment/?lang=es", "https://www.msif.org/living-with-ms/international-ms-awards/?lang=es", "https://www.msif.org/?page_id=432&lang=es", "https://www.msif.org/about-ms/symptoms-of-ms/?lang=es", "https://www.msif.org/about-ms/symptoms-of-ms/bladder-and-bowel-issues/?lang=es", "https://www.msif.org/about-ms/symptoms-of-ms/cognition-and-emotional-changes/?lang=es", "https://www.msif.org/about-ms/symptoms-of-ms/fatigue/?lang=es", "https://www.msif.org/about-ms/symptoms-of-ms/movement-and-coordination-problems/?lang=es", "https://www.msif.org/about-ms/symptoms-of-ms/pain/?lang=es", "https://www.msif.org/about-ms/symptoms-of-ms/sexual-problems/?lang=es", "https://www.msif.org/about-ms/symptoms-of-ms/vision-issues/?lang=es", "https://www.msif.org/about-ms/?lang=es", "https://www.msif.org/about-ms/what-is-ms/?lang=es", "https://www.msif.org/about-ms/epidemiology-of-ms/?lang=es", "https://www.msif.org/about-ms/types-of-ms/?lang=es", "https://www.msif.org/about-ms/childhood-ms/?lang=es", "https://www.msif.org/about-ms/causes/?lang=es", "https://www.msif.org/about-ms/diagnosing-ms/?lang=es", "https://www.msif.org/about-ms/symptoms-of-ms/?lang=es", "https://www.msif.org/about-ms/?lang=es", "https://www.msif.org/living-with-ms/?lang=es", "https://www.msif.org/research/?lang=es", "https://www.msif.org/access-to-ms-healthcare/?lang=es", "https://www.msif.org/resources/?lang=es", "https://www.msif.org/news-and-events/?lang=es", "https://www.msif.org/about-us/?lang=es", "https://www.msif.org/get-involved/?lang=es", "/", "/news-and-events", "https://www.msif.org/news/2020/10/15/a-potential-biomarker-for-progressive-ms/", "https://www.msif.org/news/2021/04/16/what-is-a-biomarker/", "https://www.msaustralia.org.au/news/ebv-progressive-ms-trial-three-years-on/", "https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-First-Participant-Dosed-in-Phase-1-Study-of-its-mRNA-Epstein-Barr-Virus-EBV-Vaccine/default.aspx", "https://esclerosismultiple.com/virus-epstein-barr-y-esclerosis-multiple-nueva-evidencia/?fbclid=IwAR0SUlyavWMl58t-TcOIe99fq_IH-wpPNYC7L9KaWOA_U9BQsHPh3rmVVjE", "https://aedem.org/ini/3903-nota-informativa-el-virus-de-epstein-barr-como-causa-de-la-esclerosis-multiple?fbclid=IwAR0IPEMsw8BBhWZkNTrTdy27kgtDTYlni_3lv6iE8amr8I84c6i2f4zb5TM", "https://www.mssociety.org.uk/research/latest-research/latest-research-news-and-blogs/more-evidence-about-role-ebv-infection-development-ms?utm_source=Facebook&utm_medium=organic_post&utm_content=EBV_research_story_fb&utm_campaign=2022M0458_1684&fbclid=IwAR1lYehgiO-9CuLBq2ImjqpiUh0BC8ty0J4HJzGEJ2m_ujWbPe8g9vHVFPU", "https://www.multiplesklerose.ch/de/aktuelles/detail/neue-erkenntnisse-zum-epstein-barr-virus-bei-ms-weitere-schritte-in-der-forschung-muessen-folgen/", "https://neuro.se/artiklar/diagnos/tunga-belaegg-foer-att-ebv-virus-orsakar-multipel-skleros/?fbclid=IwAR3lNB9H7_9UnTOUZBwuCMvIXF3x6gwaCBkUerLvmiIL6lSPLrhg1LzxRAg", "https://www.msif.org/tag/research", "https://www.msif.org/tag/treatment", "https://www.msif.org/tag/cause-of-ms", "https://www.msif.org/tag/risk", "https://www.msif.org/tag/symptoms", "https://www.msif.org/tag/ebv", "https://www.msif.org/tag/clinical-trials", "https://www.msif.org/tag/biomarker", "http://www.science.org/doi/10.1126/science.abj8222 ", "http://www.hsph.harvard.edu/news/press-releases/epstein-barr-virus-may-be-leading-cause-of-multiple-sclerosis/ ", "http://msmakedonija.eu.org/multipla-skleroza/ebv_ms/", "http://www.msif.org/wp-content/uploads/2022/03/EBV-article-polish.doc", "/contact-us", "https://twitter.com/MSIntFederation", "https://www.facebook.com/pages/Multiple-Sclerosis-International-Federation/110033075774139", "https://www.youtube.com/user/MSIFmedia", "/our-approach-to-translation", "/about-us/contact-us/?lang=es", "/terms-and-conditions/?lang=es", "/privacy-policy/?lang=es", "/complaints-policy-and-procedure/?lang=es", "/whistleblowing/?lang=es", "/site-map/?lang=es"]}